MedPath

Exploratory research on effectiveness and safety of Rituximab treatment including maintenance administration for steroid intractable autoimmune bullous diseases of the skin. Rtx-BD Trial (Rituximab of Intractable Autoimmune Bullous Disease Trial) 2

Phase 1
Conditions
Pemphigus, Pemphigoid
Registration Number
JPRN-UMIN000015451
Lead Sponsor
Department of Dermatology, Keio University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1) Pregnancy 2) Allergy for biologics 3) Severe organ disorder 4) History of other diseases which need systemic steroid treatment 5) Infections 6) Malignancy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1) A rate of severe adverse events, beyond CTCAE grade 3. 2) A rate of remission
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath